Aptorum Group Completes Merger with DiamiR Biosciences and Rebrands as Niki BioSolutions

On July 20, 2026, Aptorum Group Limited finalized its merger with DiamiR Biosciences Corp. following shareholder approval. As part of the transaction, Aptorum completed a domestication process, transitioning from a Cayman Islands exempted company to a Delaware corporation and changing its name to Niki BioSolutions, Inc. In conjunction with the merger, the company executed a 1-for-10 reverse stock split of its Class A and Class B ordinary shares. The newly formed entity, Niki BioSolutions, began trading on the Nasdaq Capital Market under the ticker symbol 'NIKI' on July 20, 2026. Under the merger terms, DiamiR stockholders received approximately 1.98 million shares of Niki common stock, while existing Aptorum shareholders were issued roughly 814,375 shares of common stock and 179,693 shares of non-voting Series A preferred stock. The company also adopted the 2026 Incentive Plan and appointed a new board of directors, with Ian Huen serving as Chairman and CEO. This strategic move consolidates DiamiR as a wholly-owned subsidiary of Niki BioSolutions.